 |
Prospector
Profile
07.1641
|
| |
| Insmed, Inc. |
NAICS |
541710 |
| 8720 Stony Point Parkway, Suite 200
Richmond, VA 23235 |
Description |
Biotechnology |
| (804) 565-3000 |
Employees |
0 |
| http://www.insmed.com |
Revenue |
(mil) |
0.9910 |
| |
Income |
(mil) |
-56.1390 |
| |
Assets |
(mil) |
28.3480 |
| |
Liability |
(mil) |
14.4680 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Insmed, Inc. had a net loss of $3.91 million for the three months ended September 30, 2007, much lower than the $12.37 million net loss reported during the three months ended September 30, 2006. For the nine months ended September 30, 2007, the Company had a $16.67 million net loss, much lower than the $34.71 million net loss incurred during the nine months ended September 30, 2006. As a result of its recurring losses, the Company has an accumulated deficit of $327.47 million as of September 30, 2007.
|
| |
|
Intellectual Property:
The Company holds 27 United States patents relating to the composition, production, antibodies and methods of use for IPLEX and rhIGFBP-3. In addition, foreign counterparts to the U.S. patents have issued or are pending issue in the major pharmaceutical markets, such as the EU, Canada and Japan. The various issued patents related to IPLEX and rhIGFBP-3 compositions, methods of production and methods of treatment expire at various times during the years 2010 through 2019. As part of the ongoing development of IPLEX, INSM-18 and rhIGFBP-3, the Company has filed or intends to file patent applications related to new production methods, improved formulations, new medical uses and new dosing regimens in the United States and in many of the major international pharmaceutical markets. [SEC Filing 10-K 03-16-07]
|
| |
|
Description:
The Company engages in the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders.
|
| |
|
Officers:
Geoffrey Allan (Chair, Pres., & CEO); Ronald D. Gunn (EVP & COO); Philip J. Young (EVP & Chief Business Officer); Kenneth Attie (VP-Medical Affairs); Andreas Sommer (Chief Scientific Officer); Kevin P. Tully (EVP & CFO); Kenneth G. Condon (Dir.); Graham K. Crooke (Dir.); Steinar J. Engelsen (Dir.); Melvin Sharoky (Dir.); Randall W. Whitcomb (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock Symbol INSM; NasdaqGM;
121,824,889 common shares outstanding as of November 1, 2007.
|
| |
| |
| |
| return to main page |
|
|
